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Abstract 
The effect of incorporating the lipidic medium-chain triglyceride (MCT) into polymeric film-
forming systems (FFS) for topical drug delivery has been evaluated. First, the in vitro release 
of betamethasone-17-valerate (BMV), a representative dermatological drug, was determined 
from FFS comprising either hydrophobic polyacrylate co-polymers, or hydrophilic 
hydroxypropyl cellulose, with and without MCT. Release was enhanced from both polymers 
in the presence of MCT. Atomic force microscopy imaging and nanoindentation of FFS with 
MCT revealed two-phase structured films with softer inclusions (0.5 to 4 µm in diameter) 
surrounded by a more rigid structure. Chemical mapping with Raman micro-spectroscopy 
showed that MCT was primarily confined to the inclusions within the polymer, which 
predominated in the surrounding film. BMV was distributed throughout the film but was more 
concentrated outside the inclusions. Furthermore, while BMV dissolved better into the 
hydrophobic films, it was more soluble in the MCT inclusions in hydrophilic films, suggesting 
its increased availability for diffusion from these softer regions of the polymer and explaining 
the release enhancement observed. Second, ex vivo skin penetration studies clearly 
revealed that uptake of BMV was higher from hydrophobic FFS than that from the more 
hydrophilic polymer due, at least in part, to the superior anti-nucleation efficiency of the 
former. Drug was quickly taken up into the SC from which it then diffused continuously over a 
sustained period into the lower, viable skin layers. In the presence of MCT, the overall uptake 
of BMV was increased and provides the basis for further optimisation of FFS as simple, 
convenient and sustained formulations for topical therapy. 
 
Keywords: Polymeric film-forming systems; topical drug delivery; atomic force microscopy; 
Raman chemical mapping; supersaturation; anti-nucleation 
Introduction 
The stratum corneum (SC) forms the outermost layer of the skin and provides a barrier to the 
delivery of adequate therapeutic drug concentrations into the skin. Usually, only a small 
percentage of the amount of drug substance applied on the skin is delivered to the target 
site, with the rest becoming unavailable for delivery because of surface loss and/or changes 
in the vehicle that prevent drug from diffusing into and through the skin [1, 2]. The treatment 
of dermatological diseases would be improved, therefore, if an increase or prolongation of 
drug delivery into the skin from topically applied formulations were possible. Polymeric film-
forming systems (FFS), created in situ after administration, offer a more efficient and patient-
friendly topical formulation with the potential to increase and/or sustain drug delivery and 
permit less frequent dosing [3-7]. Additionally, incorporation of plasticisers into FFS has been 
demonstrated to increase the in vitro release of incorporated drugs [8-11]. Given that 
increased BMV release and skin uptake with increasing plasticiser lipophilicity and higher 
MCT concentrations had been observed in earlier work [7, 12], this investigation primarily 
focused on the effect of the lipidic medium-chain triglyceride (MCT), which is a well-known 
excipient in dermatologic formulations. 
Atomic force microscopy (AFM) can provide both topographical and mechanical information 
on polymeric films at the nanoscale [11]. AFM imaging reveals film homogeneity, a key 
feature related to the contact between the skin and the drug delivery system. 
Nanoindentation uses the sensitivity of the AFM cantilever to small forces, and permits local 
mechanical properties, such as elastic modulus and hardness, to be determined. The 
approach has previously been applied to pharmaceutical excipients, such as sucrose [13], 
and to determine the effect of a topical cream on skin mechanics [14]. Chemical maps of 
polymeric films can be determined by Raman micro-spectroscopy and the spatial distribution 
of the constituents determined from characteristic spectral features. This information, in 
combination with data from AFM, provides insight into the mechanism of drug release from 
polymer films, and the impact of FFS composition (e.g., presence or absence of MCT).  
Here, the anticipated enhancement and prolongation of drug release due to the incorporation 
of the lipidic MCT into polymeric film-forming systems was studied using betamethasone-17-
valerate (BMV) as a model compound. In parallel, AFM and Raman micro-spectroscopy were 
used, respectively, to elucidate mechanistic information about the mechanical properties and 
the physical distribution of the constituents of the films.   
FFS are typically classified as either hydrophilic or hydrophobic depending on the water-
solubility of the film-forming polymer and the substantivity of the formed film on the skin 
(defined as its persistence and resistance to removal, e.g., by washing, perspiration and 
wear). Hydrophilic films must establish a drug reservoir in the skin, due to their low water-
resistance and low substantivity. Hydrophobic films, having greater water-resistance and 
substantivity, can, in principle, form a drug reservoir externally on the skin surface as well as 
within the skin itself. In this case, the two reservoirs are not easily distinguished, as the 
partitioning of drug substance from the external film into the SC and subsequently into the 
deeper skin layers are interdependent and intimately related.  A further potential advantage 
of FFS is that evaporation of its volatile constituent(s) immediately post-application can lead 
to supersaturation of the drug. While such a metastable state is thermodynamically 
unfavourable [15], rapid recrystallization of the drug [16, 17] may be retarded by excipients 
that inhibit nucleation, such as certain polymers that are known components of previously 
investigated FFS [15, 17-19]. An obvious design attribute of a FFS formulation, therefore, is 
to create a residual film in which the drug remains in a molecular (i.e., solubilised) form able 
to freely diffuse to the interface with the skin, to partition into the SC, and to continue its 
‘journey’ into the deeper skin layers.  The validity of these concepts has been examined via 
experimental measurements of the skin uptake ex vivo of BMV following delivery from 
selected FFS and from a more conventional, semi-solid, vehicle. This straightforward ex vivo 
study serves, therefore, as a penultimate step in formulation development before undertaking 
more detailed, in vivo experiments in man.   Ultimately, it is suggested that the knowledge 
derived from this work will contribute to the rationale design and optimisation of polymeric 
FFS that can provide sustained and effective topical therapy over extended periods of time. 
 
Materials and Methods 
Materials 
Betamethasone-17-valerate (BMV, purity 100%) was purchased from Crystal Pharma SAU 
(Boecillo, Spain); tritiated [1,2(n)-3H]-betamethasone 17-valerate (17.8 MBq/ml) was 
prepared by RC TRITEC AG (Teufen, Schwitzerland) and purified by LEO Pharma A/S 
(Ballerup, Denmark). The polymers used were Eudragit® RS PO (Eudragit) (ammonio 
methacrylate copolymer type B) from Evonik Röhm GmbH (Darmstadt, Germany), 
Dermacryl® 79 (Dermacryl) (acrylates/octylacrylamide copolymer) from Akzo Nobel Surface 
Chemistry AB (Stenungsund, Sweden), and Klucel™ LF (Klucel) (hydroxypropyl cellulose) 
from Azelis (Lyngby, Denmark).  Medium-chain triglyceride (Miglyol 812 N, caprylic/capric 
triglyceride) was purchased from Sasol (Hamburg, Germany), triethyl citrate (TEC) from 
Merck (Darmstadt, Germany), and methyl-β-cyclodextrin (MbCD) (Kleptose Crysmeb) from 
Roquette (Lestrem, France). White, soft paraffin and liquid paraffin were from LEO Pharma 
A/S (Dublin, Ireland), and Soluene®-350 and Hionic-Fluor were purchased from Perkin Elmer 
(Skovlunde, Denmark). Sodium acetate trihydrate and all other analytical solvents were 
purchased from VWR – Bie Berntsen A/S (Herlev, Denmark), Merck (Darmstadt, Germany) 
and Sigma-Aldrich (Broendby, Denmark). 
FFS preparation 
Film-forming solutions were prepared by dissolving the polymer, with and without 20% w/w 
MCT, in absolute ethanol (mixed with 5% w/w water for Eudragit) and stirring overnight until 
a clear solution was obtained. The concentration of MCT is expressed relative to the dry 
weight of the polymer. Drug-loaded formulations were prepared by dissolving BMV in the 
FFS with stirring at a concentration of 1.2% (w/w) (corresponding to 1.0% (w/w) 
betamethasone), which provided an infinite dose for the in vitro release tests. 
For the ex vivo skin penetration experiments, the effects of incorporating either MCT or the 
plasticiser, TEC (again at 20 % w/w relative to the dry weight of the polymer) were examined. 
The BMV mixed into the polymers was doped with the tritiated drug (final strength 1 MBq/g). 
The formulation compositions tested are in Table 1. 
Polarised optical microscopy 
Crystallisation of BMV from ethanol and from the polymeric FFS was evaluated with 
polarised optical microscopy (Nikon Eclipse 80i microscope, Nikon Corporation, Tokyo, 
Japan) equipped with 10x and 40x objectives. To facilitate visualisation of the crystals, the 
concentration of the drug in ethanol, 5% w/w Klucel, 5% w/w Eudragit and 15% w/w Eudragit 
FFS was 6.07% w/w (corresponding to 5% w/w betamethasone). A suitable volume of each 
solution was distributed on a microscope glass slide and allowed to dry at room temperature. 
The presence or absence of BMV crystals, and their distribution, was noted.  
 
Table 1 Composition of film-forming systems (all containing 1.2 % w/w BMV) tested in the ex 
vivo penetration experiments. 
Formulation constituents (% w/w) 
Polymer Klucel LF Eudragit RS Dermacryl 79 
 5.0 5.0 5.0 15.0 15.0 15.0 10.0 
      
Plasticiser/Lipid      
TEC  1.0   3.0   
MCT   1.0   3.0  
        
Solvent        
EtOH 95.0 94.0 94.0 80.0 77.0 77.0 90.0 
Water    5.0 5.0 5.0  
TEC = triethyl citrate; MCT = medium-chain triglyceride; EtOH = absolute ethanol. 
Preparation of semi-solid vehicle  
White soft paraffin (99.0 % w/w) and liquid paraffin (1.0 % w/w) were mixed at 80°C and 
allowed to cool completely before further processing. 1.2 % w/w BMV and 1 MBq g-1 3H-BMV 
were dissolved in ethanol and the solvent was then evaporated in an ultrasound water bath 
to produce relatively small (<25 µm) BMV crystals. Finally, the solid drug was dispersed in 
the paraffin ointment using a mortar.  
BMV in vitro release 
The in vitro release studies were conducted as previously described [7]. Briefly, experiments 
were conducted using modified diffusion cells (LEO Pharma A/S, Denmark), with a silicone 
membrane (Dow Corning® 7-4107 Silicone Elastomer Membrane, 75 µm) separating the 
applied FFS and the receptor medium (10% w/w solution of methyl-beta-cyclodextrin in 
acetate buffer pH 4.5). 
Atomic Force Microscopy 
AFM experiments were carried out using a Multimode Scanning Probe Microscope (Veeco, 
Plainview, NY) with a Nanoscope IIIA controller and Nanoscope software (Version 7.341).  
For AFM imaging and nanoindentation, film forming solutions with and without MCT were 
spread uniformly onto glass slides heated to 30°C to mimic the temperature of the skin 
surface. The films were then maintained at this temperature overnight. The final thickness of 
the prepared films was ~10 µm. 
Imaging 
Imaging was performed in tapping mode under ambient conditions. ‘All in One’ AFM probes 
(AlOAl, Budget Sensors, Sofia, Bulgaria), with nominal spring constants between 0.2 and 40 
N/m and resonance frequencies between 15 and 350 kHz, were used for imaging. Images 
were analysed using Nanoscope Analysis (Version 1.3, Bruker, Billerica, MA). 
Nanoindentation 
The spring constant of each AFM probe used in this study was determined using a well-
accepted approach [20]. Nanoindentation was undertaken (as described elsewhere [11]) with 
probes having spring constants between 6.1 and 8.5 N/m. The AFM probe tips were modified 
for these experiments by the electron beam induced deposition (EBID) of amorphous carbon 
in the chamber of a scanning electron microscope (SEM) (6301F, JEOL, Tokyo, Japan) [21]. 
The approach makes the probe tips rounded and their radii of curvature can be determined in 
the SEM. The shape of the indenter could therefore be modelled as spherical.  The 
maximum depth of the subsequent indentation of the polymer films was less than the radii of 
curvature of the probes selected, ranging from 27 to 80 nm.  
During the indentation process, the deflection of the cantilever, the vertical position of the 
cantilever, and time were recorded. From the resulting deformation-time data, the elastic 
modulus of the sample was determined using an adaption of the analysis developed by Oyen 
& Cook [20, 22].  
Raman Microscopy 
Samples for Raman mapping were prepared as described above but at room temperature. 
BMV was examined in solution (0.4% w/w in ethanol) and in the solid state (crystalline, as 
provided by the supplier, and amorphous forms). An amorphous film of BMV was formed by 
depositing a drop of an ethanolic solution onto a cleaned glass slide [23, 24]. 
Spectroscopic measurements were performed using a Raman microscope (inVia, Renishaw, 
Gloucestershire, UK). The excitation source was a laser operating at 532 nm. Initially, 
Raman spectra of Eudragit, Klucel, MCT, and BMV in the solid state and in solution were 
obtained using 10% of the maximum laser power available. Characteristic peaks observed in 
the Raman spectra of MCT and BMV, which were distinct from those seen in the spectra of 
the polymers, allowed their spatial distribution to be mapped.  
Raman maps (30 x 40 µm2) of polymeric films incorporating MCT were acquired. To increase 
the resolution, so that the Raman data could complement the AFM images, the excitation 
laser beam was directed to the sample via a pinhole. This reduced the area from which 
spectra were obtained to approximately 1 x 1 µm2 (equal, therefore, to the area of each pixel 
in the resulting chemical maps). Mapping was performed using the maximum laser power 
available (~80 mW); no damage to any sample was observed.  
The Raman spectra were analysed with Wire 3.4 software (Renishaw). Spectral parameters 
were defined and fitted to specific scattering peaks for MCT and BMV. The chemical 
composition of the film could then be mapped by the intensities of the MCT and BMV peaks 
at each position. The frequency of the BMV peak permitted the physical state of the drug 
within the films to be inferred. 
Skin uptake of BMV ex vivo 
As the goal was to measure drug delivery into the skin, experiments were performed on 
isolated, intact porcine ears; pig skin is an accepted surrogate for the human counterpart [1, 
25]. Franz diffusion cells with excised skin are commonly used to determine the amount of 
drug in the SC and the amount that has diffused through the skin into the receptor solution. 
In the present study, however, as the focus lay in the distribution of BMV in the SC, as 
opposed to its ability to diffuse through the skin, intact porcine ears were used to simulate the 
in vivo situation as closely as possible [26, 27]. Radiolabeled BMV allowed facile 
quantification of drug in the different skin compartments [28].  Initially, drug uptake over 24 
hours was assessed but the obvious degeneration of the tissue meant that all subsequent 
experiments were limited to a shorter duration of 8 hours. 
Preparation of pig ears 
Porcine ears were obtained from the Danish Meat Trade College (Roskilde, Denmark) shortly 
after the animals were killed. The ears had been removed before exposure to any high-
temperature cleaning procedure so as to preserve the integrity of the skin barrier. The ears 
were stored at -20°C and thawed slowly at 5°C before cleaning with water and gently 
trimming away the hair with clippers (Oster, Tennessee, USA). To minimise drying out of the 
ear during the experiment, the severed surface was wrapped in an isotonic salt-soaked cloth 
and then sealed with cling film and 3M TransporeTM Medical Tape (Copenhagen, Denmark). 
The ear was allowed to equilibrate at room temperature for 1-2 hours before application of 
formulation. To permit sequential measurements at different application times, five sites were 
delineated on each ear and considerable care was taken to ensure that the films were 
deposited within the prescribed areas. 
Skin penetration experiments 
Either 10 µl/cm2 of FFS was applied evenly on the skin (3.8 cm2) using a piston pipette 
(Gilson MICROMANTM pipette, Gilson Inc.), or 10 mg/cm2 of ointment was spread carefully 
using a spatula. The Eudragit and Klucel films created in situ remained intact while	   on the 
surface of the skin. At 15 min, 1 h, 3 h, 6 h and 8 h (Klucel FFS only to 6h) post-application, 
the remaining formulation was removed. The cleaning procedure ensured that residual 
formulation from the skin surface, and from skin furrows, was not included when quantifying 
the amount of drug in the SC [29]. For Klucel films, the skin was wiped with water-soaked 
cotton pads; for the Eudragit and Dermacryl films, one D-Squame® tape disc, applied with 
pressure for 10 s (D-Squame® pressure application, Cuderm Corporation), was used to 
remove the polymers. Ointment was removed by wiping the skin with dry cotton pads.  
The SC at the treated skin sites was removed by sequential tape stripping using D-Squame® 
tape discs, applying a pressure of 225 g/cm2 for 10 s. The SC sampling site was delimited by 
a template, which exposed an area smaller than that treated with the formulation. 
Transepidermal water loss (TEWL) was measured using a VapoMeter (Delfin Technologies, 
Kuopio, Finland) prior to and at regular intervals during tape stripping which was stopped 
when the value had increased by 10 times the initial reading or was no longer increasing. 
This procedure was validated in preliminary experiments following application of placebo 
Klucel and Eudragit FFS. In these experiments (n = 3 for each FFS), at the conclusion of 
tape-stripping, skin biopsies were taken and fixed in formalin followed by haematoxylin-eosin 
staining before microscopic evaluation to confirm the complete removal of SC [28]. The first 
tape was discarded1, and BMV was quantified on all subsequent strips. The total number of 
tapes used depended upon treatment time and individual SC thickness but was never more 
than 30. On occasion, even though TEWL had not increased to 10x baseline, it was 
observed that the epidermis began to loosen; in these cases, tape-stripping was terminated 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  With	  respect	  to	  removal	  of	  residual	  formulation	  from	  the	  skin	  surface,	  there	  remains	  an	  open	  question	  about	  whether,	   subsequent	   to	   the	  cleaning	  procedure	  adopted,	  one	  or	  more	   tape-­‐strips	   to	  complete	   the	  surface	   ‘decontamination’	  process	  should	  be	  used.	   It	  was	  decided	  to	  take	  and	  discard	  a	  single	  tape-­‐strip	  for	   this	  purpose;	  however,	  BMV	  was	   routinely	  quantified	  on	   this	   strip	   to	  gauge	   the	   impact	  of	   excluding	  this	  amount	  of	  drug	  from	  the	  total	  uptake	  eventually	  measured.	  	  As	  expected,	  this	  first	  strip	  did	  contain	  a	  significant	   and	   quite	   consistent	   quantity	   of	   BMV	   for	   the	   formulations	   tested;	   in	   terms	   of	   the	   total	   SC	  uptake,	   in	   fact,	   the	   first	   strip	   contained,	  on	  average,	  56%,	  61%,	  29%	  and	  31%	   for	   the	  Klucel,	   ointment,	  Eudragit	   and	   Dermacryl	   formulations,	   respectively.	   While	   inclusion	   of	   these	   BMV	   amounts	   in	   the	  calculated	  total	  uptake	  would	  have	  obviously	  increased	  somewhat	  the	  measured	  drug	  ‘availability’	  to	  the	  skin,	  the	  relative	  performance	  of	  the	  different	  vehicles	  examined	  would	  not	  have	  been	  affected.	  
and BMV recovered on that strip was considered to be in the epidermis. Epidermis and 
dermis were then excised and separated by heat (incubation for 7 min at 60°C and high 
humidity). For time points up to 8 hours (when the experiment was stopped), the extracted 
areas of skin were sealed with Parafilm® to prevent the ear from drying out. 
Sample analysis 
BMV was extracted from SC on the tapes and from the epidermis/dermis using Soluene® 350 
(24 h incubation at 50°C). 10 ml of Hionic-Fluor were added to the Soluene extractions and 
to the cotton pad extracts before analysis by liquid scintillation counting (Tri-Carb 2900 TR 
Liquid Scintillation Counter, Packard Instrument Company, Meriden, USA). Hionic-Fluor 
alone provided the necessary background measurements.  
Data analysis  
All statistical analyses were performed with GraphPad Prism 5.01. Two-way ANOVA (p < 
0.05) followed by Bonferroni post-test was used to compare means. 
 
 
Results 
BMV release in vitro 
BMV release was determined for FFS with and without MCT. Previous experiments have 
investigated BMV release from Eudragit (hydrophobic) and Klucel (hydrophilic) films 
incorporating the plasticizer TEC [7]. The prepared films all sustained BMV release over 72 
hours, with the incorporation of MCT causing significant enhancement that became apparent 
from about 6 hours into the experiment (Figure 1). Release from Eudragit films followed t½ 
kinetics, consistent with previous observations [7], with MCT resulting in an increase in the 
rate from 0.45 to 2.19 µg cm-2 h-½. For the Klucel films, the release was zero-order (again, as 
had been seen before [7]) and the incorporation of MCT enhanced the rate from 0.58 to 1.56 
µg cm-2 h-1. 
Square root of time (h1/2)
0 2 4 6 8 10C
um
ul
at
iv
e 
B
M
V
 re
le
as
ed
 (m
g 
cm
-2
)
0
5
10
15
20
25
Eudragit
+ 20% MCT
a
Time (h)
0 20 40 60 80C
um
ul
at
iv
e 
B
M
V
 re
le
as
ed
 (m
g 
cm
-2
)
0
30
60
90
120
150
Klucel
+ 20% MCT
b
 
Figure 1. In vitro release of BMV from (a) Eudragit, and (b) Klucel film-forming systems with 
and without medium-chain triglyceride (MCT) (mean ± standard deviation, n=3). 
 
 
AFM images of polymeric films 
The topography of the films deposited on glass slides was imaged with AFM in tapping mode 
(Figure 2). The Eudragit film without MCT was relatively smooth (variations in height of the 
observed structural features being only about 1-2 nm) with a root mean square (RMS) 
roughness of 0.7 nm. Klucel films had a distinctly different, and less smooth appearance, 
with an RMS roughness of 4.6 nm [11].  
Incorporation of MCT (Figure 2) significantly changed the topography of the polymeric films. 
For Eudragit, there were regions (hereinafter referred to as inclusions) where the structure 
appeared to dip into the sample surface. These ellipsoidal inclusions ranged from 0.5 to 1.0 
µm in diameter. Similar structures were seen in the Klucel films although, in this case, the 
inclusions appeared above the surrounding material and were larger (2 - 4 µm in diameter) 
than those observed with Eudragit.  
Nanoindentation 
During AFM nanoindentation, indents were separated by at least 250 nm along the sample 
surface to ensure that each new indent would deform a previously unaffected area of the 
film.  The load (P) applied to the sample by the probe tip was calculated using the cantilever 
spring constant. The sample deformation (h) at a given cantilever deflection (D) was found 
from the difference in cantilever vertical position between the calibration and sample 
indentation curves.   
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Figure 2. Pseudo 3D AFM images of Eudragit ((a) and (b)) and Klucel ((c) and (d)) FFS, cast 
onto glass microscope slides, with ((b) and (d)) and without ((a) and (c)) 20% w/w MCT 
incorporated [7]. The scan size was 4 x 4 µm2 for the films without MCT and 10 x 10 µm2 for 
those with. 
 
The load-deformation behaviour for films with and without MCT (Figure 3) provides the 
information necessary to select a model with which to fit the data and to extract the elastic 
moduli of the samples. The results reveal (i) the significantly different nanoindentation 
behaviour of films incorporating MCT, and (ii) that there is greater deformation at a given 
load of the softer inclusions than that of the more rigid surrounding areas (the mechanical 
properties of which are very similar to those of pure polymer films). For example, at a load of 
50 nN, the deformation of Eudragit with 0% MCT (Figure 3(a)) is 2 nm. This is the same as 
the deformation of areas surrounding the inclusions in Eudragit films containing MCT at this 
load. The deformation of the inclusions within these films is greater, at 7 nm. Similarly, the 
deformation of the inclusions within Klucel films incorporating MCT (Figure 3(b)) at a load of 
50 nN is 10 nm. This is greater than the deformation in the areas surrounding the inclusions 
and in Klucel films without MCT; namely, 6 and 5 nm, respectively. 
The larger hysteresis in the load-deformation plots from the inclusions compared to the 
behaviour of films without MCT is also consistent with their more pronounced viscous-plastic 
behaviour (i.e., that they are ‘softer’). The latter can be characterised using an effective 
hardness (He): 
He = Pmax/A 
where Pmax is the maximum load on the sample, and A is the effective projected area of the 
indent when P = 0 [30].  The projected area is calculated from 
A = (2 × π × R × hf) – (π x hf2) 
where R is the radius of curvature of the indenter and hf is the residual deformation when P = 
0. The effective hardness for the inclusions in Eudragit and Klucel films were 0.13 (±0.02) 
and 0.037 (±0.007) GPa, respectively. In contrast, the corresponding He values for the areas 
surrounding the inclusions were 0.23 (±0.04) and 0.070 (±0.010) GPa. The effective 
hardnesses of the two polymers demonstrates the softer nature and the more pronounced 
viscous-plastic behaviour of Klucel films which require a lower load to deform non-elastically. 
The load-deformation behaviour of the inclusions in Eudragit and Klucel films shows distinct 
deformation characteristics. This implies that the inclusions not only comprise MCT and 
BMV, but must also contain some quantity of the respective polymer too.  
The Oyen & Cook model, to interpret the nanoindentation data of viscous-elastic-plastic 
materials, has been adapted for spherical indentation [22]. This approach considers the total 
deformation of the sample as the sum of viscous, elastic and plastic deformations. Details of 
the deformation analysis and the adapted model have been published [11], and the total 
deformation during the unloading at a constant rate (hUNLOAD(t)) is given by: 
hUNLOAD(t) = {[(3×Pmax)/(4 × R1/2 ×τU)] × Er-2/3 × (∆t)2/3} + {b × (∆t)5/3} + c  (1) 
where ∆t = τL + τU – t, and t is the time of the measurement, τL and τU are the loading and 
unloading times, respectively, Er is the reduced elastic modulus of the sample, and b and c 
are constants, the former depending on the geometry of the probe and the viscosity of the 
medium. Equation (1) was fitted to the unloading data (see examples in Figure 3) and Er was 
determined. Examples of fits of this model to the experimental data are shown in Figure 3.  
Er takes into account the elastic modulus of the indenter and of the sample itself. As the 
indenter moduli (150 GPa for silicon [31] and 28 GPa for EBID [21]) were much greater than 
those of the samples (0.01-1.9 GPa), the elastic modulus of the sample (E) is approximately 
given by:  
E = Er × (1 – ν2)        (2) 
where ν is its Poisson’s ratio (equal to 0.495 for Eudragit and Klucel polymer films [32]). 
Elastic moduli of the films were determined based upon at least 10 indents on each of three 
samples. The values for Eudragit and Klucel films without MCT were 1.2 (±0.3) and 1.7 
(±0.5) GPa, respectively. When 20% MCT was incorporated, the corresponding elastic 
moduli were 0.29-2.31 GPa and 0.31-2.37 GPa, respectively.  
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Figure 3. Load as a function of deformation during indentation of (a) Eudragit ± MCT, and (b) 
Klucel ± MCT. Examples of indents from areas from within and from outside the observed 
inclusions are shown. Data in black were collected as the load on the sample was increased 
(indicated by black arrows), while those in grey were recorded as the probe was retracted 
and the load decreased (grey arrows). The black lines intersecting grey data points for 
inclusion indents are model fits to the unloading data for the films with MCT. 
 
Figure 4 shows the variation of elastic moduli across the polymer films with MCT.  Indents 
were taken every 250 or 500 nm on a line along the film surface.  As anticipated by the 
preceding discussion, the elastic moduli vary according to whether the indents were taken on 
inclusions (indicated by diagonal line shading in Figure 4) of lower elastic moduli, or on the 
surrounding material. The distance over which lower elastic moduli were measured agrees 
closely with the diameter of the inclusions observed in the AFM images. 
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Figure 4. Elastic modulus as a function of position along a line of indents in Eudragit and 
Klucel films containing 20% MCT.  Areas shaded with diagonal lines are considered to be 
inclusions. The elastic moduli of polymeric films without MCT are shown as horizontal black 
lines with grey shading indicating the corresponding standard deviations. 
 Raman micro-spectroscopy 
Raman spectra 
Characteristic peaks for each component of the films were identified from Raman spectra 
(Figures 5(a) and (c)). Spectra from inclusions and from the areas surrounding them in 
Eudragit and Klucel polymeric films were also recorded (Figures 5b and 5d). The presence of 
MCT in Eudragit films substantially increased the Raman signal between 2850 and 2890 cm-
1 and the value at 2880 cm-1 was selected to monitor the distribution of this compound in the 
hydrophobic films.  In the case of Klucel, a different peak (at 1745 cm-1) was used for MCT 
due to overlap in the spectra at the higher wavenumber. For BMV, a peak around 1670 cm-1, 
was used to map the distribution of drug in both polymeric films in the presence of MCT. The 
signal from the drug at higher wavenumbers (2800-3100 cm-1) was of insufficient intensity to 
be of use. 
Raman maps 
The inclusions in the polymer films were smaller when the substrate was heated to 30°C than 
those observed at room temperature. As larger inclusions facilitated the Raman 
measurements (the resolution of the optical microscope being much lower than that of the 
AFM), chemical mapping was performed on films produced at room temperature. 
Maps of the distributions of MCT and BMV in films are in Figure 6. Brighter pixels imply 
greater Raman signal intensity and hence greater concentration of the corresponding 
molecule. The MCT maps show that the level of this chemical was enhanced within the 
previously identified inclusions (Figures 6(a) and (b)). BMV was distributed throughout the 
films but more drug was apparent in the areas surrounding the inclusions (Figure 6(c) and 
(d)). The concentration of MCT varied by 50% in Eudragit films, from a normalised intensity 
of 1 (green pixel, the inclusions) to a normalised intensity of 0.5 (black pixel, the 
surroundings), and by 74% in Klucel films. The variation in BMV concentration in the films 
was less than for MCT: 25% and 44% in Eudragit and Klucel films, respectively. 
Representative variations in the intensity of the MCT and BMV signals along a line of the 
maps are illustrated in Figure 6(e). 
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Figure 5. Raman spectra of (a) the individual constituents of the polymeric films (Eudragit, 
Klucel, MCT and BMV, and of (b) inclusions and the areas surrounding them in Eudragit and 
Klucel films incorporating MCT. Spectra have been normalised to the maximum intensity 
within the ranges shown, i.e., 750-1800 cm-1 and 2750-3120 cm-1, and offset to facilitate 
visualisation. Arrows indicate the position of characteristic peaks for MCT and BMV. 
 A shift in the position of the characteristic BMV Raman peak was observed as a function of 
physical the state of the drug: from 1659.4 cm-1 and 1662.6 cm-1 for crystalline and 
amorphous solid forms, respectively, to 1665.8 cm-1 for the compound in solution (Figure 
7(a)). Raman maps of the Eudragit and Klucel films containing MCT were produced focusing 
on the position of the BMV peak. In Eudragit, the drug peak position was essentially constant 
(1671.3 (±0.1) cm-1) across the film. In contrast, in Klucel, the BMV peak varied from 1667.0 
(±0.2) cm-1 in the inclusions to 1666.3 (±0.1) cm-1 in the surrounding areas (Figures 7(b) and 
(c)). 
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Figure 6. Raman chemical maps of the distributions of MCT and BMV in polymer films. The 
distributions of MCT in Eudragit and Klucel are shown in (a) and (b), respectively; the 
corresponding distributions of BMV are in (c) and (d). Brightly coloured green (MCT) and red 
(BMV) pixels indicate higher concentrations; black pixels reflect areas of lower 
concentrations. White boxes in the maps highlight areas with clear differentiation in chemical 
levels. The variations of Raman signals from MCT and BMV along the lines drawn across the 
maps are shown in (e), with the positions of inclusions indicated by diagonal shading. Scale 
bar represents 5 µm. 
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Figure 7. (a) Raman micro-spectroscopy of crystalline, amorphous and dissolved BMV. 
Spectra have been normalised within the range shown.  (b) Raman map of the peak position 
of the BMV signal from a Klucel film containing MCT: the brightest pixels originate from an 
average peak position of 1667.6 cm-1, while the dark pixels correspond to 1665.8 cm-1. Scale 
bar represents 5 µm. (c) Representative BMV spectra from bright and dark pixels in the 
Raman map of a Klucel film and from a pixel in the Raman map of a Eudragit film. (d) 
Position of the peak characteristic of BMV in Eudragit and Klucel films along representative 
lines of their Raman chemical maps. Diagonally shaded areas indicate the presence of 
inclusions. 
 
Skin uptake of BMV ex vivo 
The total amount of BMV delivered into the skin (SC + epidermis + dermis) was significantly 
higher (p < 0.05) from the Eudragit FFS than either the Klucel FFS or the simple ointment 
(Figure 8(a)). The difference between Eudragit and the other formulations was mostly due to 
drug present in the SC, while the distribution into the deeper skin layers was quite similar for 
the three vehicles (see Supplementary Information, Figure S1). The uptake of BMV from the 
formulations was relatively rapid, and increased only modestly after the first 15-60 minutes of 
application. 
 
 Figure 8. Skin penetration profiles of BMV after: (a) application of Klucel and Eudragit FFS 
and of a simple ointment; (b,c) after application of Klucel FFS (b) and Eudragit FFS (c) with 
and without TEC and MCT (BMV distribution into the individual skin layers (SC, epidermis, 
dermis) is shown in the Supplementary Information, Figures S2 and S3); (d) application of 
hydrophobic Eudragit and Dermacryl FFS. All values presented are the mean ± standard 
deviation of 4 replicates. Asterisks mark significant increases in skin uptake, relative to FFS 
without MCT.  
 
Incorporation of the plasticiser (TEC) or the lipid excipient (MCT) into the Klucel and Eudragit 
FFS did not significantly increase BMV delivery until the period of application had reached 6 
or 8 hours (Figures 8(b) and (c)) (at which point, the presence of MCT produced a significant 
increase in skin uptake (p < 0.05)). 
Given that BMV delivery to the skin was greater from the more hydrophobic FFS based on 
Eudragit, the skin uptake of the drug was next examined from Dermacryl, an even more 
hydrophobic, anionic polyacrylate polymer. Like Eudragit, Dermacryl is amorphous [33], 
produces a FFS of low viscosity that dries to form a smooth film. In vitro, across an inert 
membrane, Dermacryl released BMV quickly at first (2.2 ± 0.4 µg cm-2 in 1 hour) but by 72 
hours had not liberated more drug than Eudragit (4.3 ± 1.2 µg cm-2). The Dermacryl FFS 
investigated contained 10 % w/w of polymer and did indeed deliver significantly more BMV to 
the skin than Eudragit as shown in Figure 8(d). It was noted, however, that the amounts 
measured in the individual skin layers did not always reveal the same significant differences 
at all time points (see Supplementary Information, Figure S4). 
BMV crystallization from polymer films 
When the Klucel and Eudragit FFS were deposited on glass slides and allowed to dry, 
formation of BMV crystals were observed for both formulations as the films dried (see 
Supplementary Information, Figure S5).  However, there were consistently fewer crystals 
seen in the Eudragit films as compared to those of Klucel. The crystal forms were also 
different: triangular/pyramidal habit for Klucel, irregular-shaped for Eudragit.  Furthermore, 
when the Eudragit concentration in the FFS was increased from 5 to 15% w/w, the extent of 
crystallisation was decreased. 
 
 
Discussion 
In previous work, it was shown that the in vitro release of BMV was higher from a Klucel FFS 
than from Eudragit, and that drug release from both polymer films increased with increasing 
lipophilicity of the incorporated plasticiser [7]. In this work, the highly lipophilic MCT was 
formulated into the polymeric films, and the mechanism of enhanced drug release was 
elucidated. BMV release from both Klucel and Eudragit FFS incorporating MCT was 
significantly higher from ~6 h into the experiment (Figure 1). At 72 h, drug release from 
Eudragit and Klucel had been enhanced by 4.5- and 2.5-fold, respectively.  
AFM and Raman micro-spectroscopy were undertaken to determine the mechanism of 
enhanced BMV release when MCT was incorporated into Eudragit and Klucel FFS. Earlier 
work [11] had shown that the plasticiser, triethyl citrate (which can reduce the glass transition 
temperature of polymeric films) distributed predictably and evenly throughout the polymer 
network. In contrast, AFM and nanoindentation experiments revealed the formation of a two-
phase structure with inclusions when MCT was incorporated into Eudragit and Klucel films 
(Figure 2). The size of the inclusions was influenced by polymer viscosity and the 
temperature (and hence the rate of solvent evaporation) at which the films were prepared. 
For instance, larger inclusions are observed in the more viscous Klucel FFS prepared at 
lower temperature. In addition, the relatively poor miscibility of MCT with this more 
hydrophilic polymer encourages the apparent phase separation in the film and the creation of 
larger inclusions. The elastic moduli of those areas of the films surrounding the inclusions 
were similar to those of the polymers without MCT; on the other hand, the elastic moduli of 
the inclusions were more than three times smaller (Figure 4). Raman mapping demonstrated 
clearly that MCT was principally found within the inclusions; the surrounding areas comprised 
primarily polymer and BMV and a small proportion of MCT (Figure 5). 
In Eudragit films with and without MCT, the peak of the BMV Raman signal was the same in 
all areas (1671.25 ± 0.11 cm-1) implying that incorporation of MCT did not change the 
solubility of the drug in this hydrophobic polymer. Furthermore, the fractional area occupied 
by inclusions with respect to the total film area 0.26 (±0.15) and 0.33 (±0.03) for Eudragit and 
Klucel, respectively) was not significantly dependent upon the nature of the polymer. The 
observed enhancement in drug release rate may therefore be attributed to the presence of 
inclusions, their softer nature, perhaps, allowing for a higher BMV diffusivity.  
For the Klucel films, the peak Raman signal from BMV (1666.26 ± 0.09 cm-1) indicated that it 
was present in the same dissolved state in both the pure polymer and in the areas 
surrounding the inclusions in the polymer when MCT was present. Within the inclusions, the 
shift in the peak signal (to 1667.0 ± 0.2 cm-1) suggests that the ratio of dissolved to 
suspended drug was somewhat increased. This observation, coupled with the 
nanoindentation results showing the softer environment of the inclusions in Klucel (as was 
also seen for Eudragit), is again consistent with the enhanced release from the film in the 
presence of MCT. It is also noted that the difference in hardness between the inclusions and 
the surrounding areas of the Klucel film was smaller than that for the hydrophobic Eudragit 
FFS and this may explain why the relative (or fold-) improvement in drug release rate from 
Eudragit is more marked.  
In terms of BMV delivery to the skin, Eudragit FFS delivered significantly more drug than the 
Klucel formulation at all times (Figure 8(a); at ≥0.25 h, p < 0.001). Importantly, the Eudragit 
FFS also significantly out-performed the conventional ointment (>0.25 h, p < 0.05) to a 
similar extent suggesting the potential to improve dermatological therapy. The amounts of 
BMV delivered to the skin in this study from the polymer films compare favourably with that 
found (1.4 µg/cm2) after a 24-hour application of a commercial cream (Betnovate®) [34]. This 
observation supports the clinical relevance of the performance of the FFS examined here.  
The superior outcome achieved with the more hydrophobic FFS (i.e., Eudragit) merits further 
analysis, particularly in light of previously published in vitro experiments [7], using an inert 
membrane, that showed a higher release of BMV from Klucel. At one level, such a 
divergence of behaviour confirms that there is no simple way to model the complex 
interactions between a formulation and the skin post-application, and that the value of in vitro 
release testing (IVRT) rests in its use as a tool for quality control, not for assessment of 
bioavailability and/or bioequivalence. The precise mechanism underlying the difference seen 
between IVRT and ex vivo measurements cannot be deduced unequivocally from the data 
obtained. Undoubtedly, the physical events occurring post-application of the FFS and the 
creation of the films are crucially dependent upon the formulation composition and 
characteristics and the nature of and the interactions with the surface onto which they are 
applied. 
Immediately after the FFS is applied to the skin, the volatile solvent begins to evaporate, 
rapidly concentrating the drug, and decreasing its solubility in the vehicle to the point that 
saturation is reached. At this point, two scenarios are apparent: either the drug crystallises, 
or comes out of solution in amorphous form, or a transient, metastable, supersaturated state 
is formed before eventually reverting to the thermodynamically favoured situation of simple 
saturation. In both instances, drug uptake into the SC is driven as the solvent evaporates, 
and this phenomenon is manifested in the penetration profiles in Figure 8, which shows 
significant BMV entry into the skin within the first 15-60 minutes of application. 
It is well known that certain polymers can help to stabilise, albeit transiently, a supersaturated 
drug solution and both Klucel [35] and Eudragit [16, 36] have been shown capable of this 
behaviour. Anti-nucleation efficiency of such polymers has been related to the creation of 
hydrogen (H)-bonds between the drug and the anti-nucleant [15, 23, 37]. The BMV 
crystallisation results, taken together with the higher delivery of drug, suggest that Eudragit 
may be able to stabilise the drug in a transient, supersaturated state better than Klucel. 
Inspection of the structures of the two polymers and that of the drug suggests that the H-
bond donating –OH groups in BMV are matched by the H-bond accepting amine groups in 
Eudragit [36, 38], the equivalent of which are not found in Klucel [39]. Further support for this 
interpretation comes from the skin penetration data from FFS based on Dermacryl (Figure 
8(d)), which performs even better than Eudragit in delivering BMV to the skin, an effect that 
can be attributed to the strongly H-bond accepting amide groups present in this polymer.  
The superior performance of the hydrophobic, acrylate-based FFS is additionally 
underpinned by the generally higher solubilisation of BMV in these formulations (as 
compared to those with Klucel) (Figure 7(d)) and the amorphous nature of the solid drug in 
Eudragit. 
Taken together, therefore, the above factors result in a superior drug delivery performance 
by Eudragit and Dermacryl, with a transient period of BMV supersaturation achieved that 
permits establishment of a drug reservoir in the SC from which a sustained, but slower, 
release over an extended period of time may be achieved; equally, the more favourable 
solubility characteristics of BMV in the residual formulations of these hydrophobic polymers 
on the skin surface ensures that the drug can continue to be made available after the 
‘metamorphosis’ [2] of the FFS has been completed. 
With respect to incorporation of a plasticiser, or a lipid excipient, into the FFS, while TEC has 
been shown to increase the release of BMV from polymeric films in vitro [7], the plasticiser 
did not increase the skin penetration of the drug (p > 0.05). Nonetheless, TEC does impart 
flexibility to the film [11], an important feature with respect to the comfort of the drug delivery 
system on the skin. IVRT of polymeric FFS indicated that drug liberation increased with 
increasing lipophilicity of the incorporated plasticiser [7]. MCT was also rather effective when 
included in the FFS tested and this ability was confirmed in the ex vivo experiments 
described here: significant improvement (p < 0.05) in BMV delivery into the skin was 
observed (Figures 8(c) and 8(d)) for both Klucel and Eudragit FFS at the longest applications 
studied (6 and 8 h, respectively). 
Finally, further consideration of the AFM nanoindentation studies of Klucel and Eudragit 
polymeric films incorporating MCT and the biphasic structure with the lipid excipient 
concentrated into inclusions. While these measurements were made on films cast on a glass 
slide, it is plausible to anticipate that the observed phase separation, at least to some extent, 
also occurs when the polymeric films are formed on skin. This would mean that BMV 
solubilised in the mechanically softer inclusions might be more easily and rapidly released 
(relative to the more rigid polymeric surroundings). Raman micro-spectroscopic mapping of 
Klucel and Eudragit films incorporating MCT showed that the relative distribution of MCT in 
Klucel was approximately 4:1 in favour of the inclusions (relative to the ‘stiffer’ surroundings), 
but was only about 2:1 for Eudragit. The corresponding values for BMV were roughly 2:1 (in 
Klucel) and ~1.3:1 (in Eudragit) in favour of the areas surrounding the inclusions. As a result, 
the drug-to-excipient ratios in Klucel and Eudragit were 0.46 and 0.64, respectively (a 
schematic illustrating these calculations is provided in the Supplementary Information, Figure 
S6). The implications of these findings are (at least) two-fold. First of all, as one might 
expect, the miscibility of the lipid excipient in Eudragit is superior to that with the more 
hydrophilic Klucel. Second, even though the higher MCT level in the Klucel inclusions makes 
these regions softer than the corresponding areas in the Eudragit films, more BMV is found 
in the latter and this means that drug delivery from the hydrophobic FFS is the most efficient. 
Overall, therefore, one can conclude that the judicious incorporation of a lipophilic excipient 
into a FFS formulation can enhance the delivery of relatively lipophilic drugs into the skin. 
 
Conclusions 
 
The drug release enhancing effect of MCT in vitro when incorporated in Eudragit and Klucel 
FFS has been demonstrated, and AFM and Raman micro-spectroscopy have provided 
complementary information on the mechanism by which this is achieved. The films adopt a 
two-phase structure when MCT is present, comprising softer inclusions within a surrounding, 
more solid polymeric network. MCT is primarily located within the soft inclusions. BMV 
distributes throughout the films, but at relatively higher levels in the polymeric network 
surrounding the inclusions. Enhanced drug release from the films in the presence of MCT 
was attributed to the formation of the inclusions, their softer environment presumably leading 
to a higher diffusivity of the drug. BMV appears to be more soluble (relative to the 
surrounding areas) in the inclusions in Klucel films from which drug release was highest.   
The topical delivery of a common, lipophilic corticosteroid (BMV) into the skin from these 
polymeric films (FFS) formed in situ was subsequently demonstrated. The superior 
performance of FFS formed with hydrophobic polymers, specifically Eudragit and Dermacryl, 
is apparent (relative to a FFS prepared with the more hydrophilic Klucel). The results suggest 
that the rapid skin uptake of the drug is facilitated by a transient period of supersaturation 
favoured by hydrogen bond interactions between BMV and the hydrophobic acrylate 
polymers employed. It is suggested that this mechanism allows for the establishment of drug 
‘reservoirs’ both in the residual polymeric film on the skin surface, and within the stratum 
corneum, from which sustained delivery can then be maintained over an extended period. 
Incorporation of a lipophilic excipient (medium-chain triglyceride) into the hydrophobic 
polymer films enhances BMV uptake into the skin at the longer periods of application 
considered.  In summary, the research described provides a foundation upon which further 
formulation development and optimisation can be based and more detailed studies may be 
planned in vivo. 
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Supplementary Figure S1. Penetration profiles of BMV into the (a) SC, (b) epidermis and 
(c) dermis after topical application of FFS and ointment (mean ± standard deviation; n=4). 
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Supplementary Figure S2. Penetration profiles of BMV into the (a) SC, (b) epidermis and 
(c) dermis after topical application of Klucel FFS with and without TEC and MCT, plasticizer 
and lipid, respectively (mean ± standard deviation; n=4). 
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Supplementary Figure S3. Penetration profiles of BMV into the (a) SC, (b) epidermis and 
(c) dermis after topical application of Eudragit FFS with and without TEC and MCT, 
plasticizer and lipid, respectively (mean ± standard deviation; n=4). 
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Supplementary Figure S4. Penetration profiles of BMV into the (a) SC, (b) epidermis and 
(c) dermis after topical application of hydrophobic FFS, Eudragit and Dermacryl (mean ± 
standard deviation; n=4). 
 
  
 
Supplementary Figure S5. Representative micrographs showing BMV crystallisation from 
polymeric FFS: (a) 5% w/w Klucel, (b) 5% w/w Eudragit  and (c) 15% w/w Eudragit. The 
concentration of the drug in ethanol, 5% w/w Klucel FFS, 5% w/w Eudragit  FFS and 15% 
w/w Eudragit FFS was 6.07% w/w (corresponding to 5% w/w betamethasone).  Scale bar 
represents 50 µm.  
 Supplementary Figure S6. Schematic representation (not to scale) of biphasic Klucel 
(upper panel) and Eudragit (lower panel) films. The shaded and white areas represent the 
‘rigid’ surroundings and the softer inclusions, respectively. The relative distributions of MCT 
and BMV in the inclusions and the surroundings have been deduced from Raman chemical 
mapping.  Note that this illustration of the inclusions assumes that they are cylindrical in form; 
this may not necessarily be the case (e.g., they may be spherical or ovoid) and this would 
alter (quantitatively but not qualitatively) the calculated relative distributions of MCT and 
BMV. 
 
 
